KRYS Share Price Performance
US$261.80
74.91 (40.08%)
10.1% undervalued intrinsic discount
US$291.22
Fair Value
Price US$261.80
AnalystConsensusTarget US$291.22
unknown US$233.91
AnalystHighTarget US$336.00
Fair ValueUS$291.22
Share Pricen/a
Krystal Biotech, Inc. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 58 Fair Values set on narratives written by author
KRYS Community Narratives
AN
Fair Value US$291.22 10.1% undervalued intrinsic discount
KRYS: Global Expansion And Pipeline Shifts Will Shape Near-Term Performance
0users have liked this narrative
0users have commented on this narrative
22users have followed this narrative
UN
Fair Value US$233.91 11.9% overvalued intrinsic discount
The Rare Disease Rocket Ship
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$336 22.1% undervalued intrinsic discount
Aging Populations And AI Will Accelerate Gene Therapy Adoption
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
The Rare Disease Rocket Ship
Krystal Biotech reports tomorrow, February 17, 2026. The narrative is no longer about survival; it’s about dominance.Read more
20
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
KRYS: Global Expansion And Pipeline Shifts Will Shape Near-Term Performance
Key Takeaways International launches and broad pipeline expansion are set to diversify revenue streams and enhance market presence beyond a single product. Manufacturing efficiencies and favorable global healthcare trends are likely to increase profitability and support sustained premium pricing.Read more
241
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
22users have followed this narrative
AN
US$291.22
10.1% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
33.38% p.a.
Profit Margin
49.96%
Future PE
23.22x
Price in 2029
US$353.97
Aging Populations And AI Will Accelerate Gene Therapy Adoption
Key Takeaways Rapid market penetration and strong operational scalability for VYJUVEK are expected to substantially increase revenue, margins, and earnings power beyond current analyst expectations. Robust pipeline progress, first-mover advantages, and AI-driven patient engagement initiatives could unlock multiple high-margin revenue streams and greater long-term growth.Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$336
22.1% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
53.07% p.a.
Profit Margin
67.68%
Future PE
13.21x
Price in 2029
US$408.51
Uncertain Gene Therapy Dynamics Will Fuel Challenges Yet Spark Hope
Key Takeaways Reliance on Vyjuvek faces challenges from unpredictable patient treatment patterns, pricing pressures, and reimbursement risks, impacting both revenue visibility and long-term margin stability. Expanding into new indications through the pipeline and broader patient access drives costs and risk, particularly given high R&D investment and dependence on successful clinical outcomes.Read more
21
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$202
29.6% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
21.08% p.a.
Profit Margin
42.54%
Future PE
25.49x
Price in 2029
US$245.22
Trending Discussion
Recently Updated Narratives
UN
The Rare Disease Rocket Ship
Fair Value: US$233.91 11.9% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
KRYS: Future Returns Will Reflect Vyjuvek Penetration And CF And Oncology Pipeline Execution
Fair Value: US$291.22 10.1% undervalued intrinsic discount
22 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
KRYS: Future CF Data Readouts May Redefine Long Term Upside Potential
Fair Value: US$336 22.1% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Krystal Biotech, Inc. Key Details
About KRYS
- Founded
- 2016
- Employees
- 295
- CEO
- WebsiteView website
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
